Atara Biotherapeutics, Inc (ATRA) insider trading

Every open-market stock purchase and sale by Atara Biotherapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Brian N Cherry (Insider) bought $1M in the last 90 days, more than doubling their stake.
  • AnhCo Nguyen (CEO) sold $40.9K in the last 90 days.

Last 12 months: insiders bought $5.7M (2 buys) and sold $3.9M (9 sales). Last close $9.35 on Oct 21, 2026.

Recent ATRA insider trades

DateInsiderTradeValue
Sep 4, 2026Brian N Cherry (Insider)Bought$1M
Aug 17, 2026AnhCo Nguyen (CEO)Sold$40.9K
Jul 22, 2026Redmile Group LLC (Director)Bought (not open market)—
Jul 22, 2026Redmile Group LLC (Director)Sold (not open market)—
Jul 22, 2026Redmile Group LLC (Director)Bought (not open market)—
Jul 22, 2026Redmile Group LLC (Director)Bought (not open market)—
Jul 22, 2026Redmile Group LLC (Director)Bought (not open market)—
Jun 11, 2026Brian N Cherry (Insider)Bought (not open market)—
Jun 9, 2026Gregory Austin Ciongoli (Insider)Bought (not open market)—
Jun 9, 2026Matthew K Fust (Insider)Bought (not open market)—
Jun 9, 2026William K Heiden (Insider)Bought (not open market)—
May 18, 2026AnhCo Nguyen (CEO)Sold$47.8K
May 18, 2026Yanina Grant-Huerta (C-suite exec)Sold$22K
May 7, 2026EcoR1 Capital LLC (10% owner)Bought$4.7M
May 7, 2026Panacea Innovation Ltd (Insider)Sold$3.2M
Mar 17, 2026Panacea Innovation Ltd (Insider)Bought (not open market)$1.7M
Mar 17, 2026Panacea Innovation Ltd (Insider)Sold (not open market)$26
Mar 9, 2026Yanina Grant-Huerta (C-suite exec)Bought (not open market)—
Mar 9, 2026AnhCo Nguyen (CEO)Bought (not open market)—
Mar 2, 2026Yanina Grant-Huerta (C-suite exec)Sold$8.1K
Mar 2, 2026AnhCo Nguyen (CEO)Sold$7.3K
Mar 2, 2026AnhCo Nguyen (CEO)Sold$6.6K
Mar 2, 2026Yanina Grant-Huerta (C-suite exec)Sold$1.9K
Mar 2, 2026AnhCo Nguyen (CEO)Sold$1K
Mar 2, 2026Yanina Grant-Huerta (C-suite exec)Sold$508

Who's trading ATRA

Get free alerts when an insider at Atara Biotherapeutics, Inc files a new trade →